235 related articles for article (PubMed ID: 29188518)
1. Screening for Neutralizing Antibodies Against Natural and Engineered AAV Capsids in Nonhuman Primate Retinas.
Day TP; Byrne LC; Flannery JG; Schaffer DV
Methods Mol Biol; 2018; 1715():239-249. PubMed ID: 29188518
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing Antibodies Against Adeno-Associated Virus (AAV): Measurement and Influence on Retinal Gene Delivery.
Desrosiers M; Dalkara D
Methods Mol Biol; 2018; 1715():225-238. PubMed ID: 29188517
[TBL] [Abstract][Full Text] [Related]
3. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
[TBL] [Abstract][Full Text] [Related]
4. Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies.
Calcedo R; Franco J; Qin Q; Richardson DW; Mason JB; Boyd S; Wilson JM
Hum Gene Ther Methods; 2015 Jun; 26(3):103-5. PubMed ID: 26067568
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal injection of a rationally designed AAV capsid library in non-human primate identifies variants with enhanced retinal transduction and neutralizing antibody evasion.
Kellish PC; Marsic D; Crosson SM; Choudhury S; Scalabrino ML; Strang CE; Hill J; McCullough KT; Peterson JJ; Fajardo D; Gupte S; Makal V; Kondratov O; Kondratova L; Iyer S; Witherspoon CD; Gamlin PD; Zolotukhin S; Boye SL; Boye SE
Mol Ther; 2023 Dec; 31(12):3441-3456. PubMed ID: 37814449
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
[TBL] [Abstract][Full Text] [Related]
7. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
Giles AR; Govindasamy L; Somanathan S; Wilson JM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
[TBL] [Abstract][Full Text] [Related]
8. Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5
Majowicz A; Salas D; Zabaleta N; Rodríguez-Garcia E; González-Aseguinolaza G; Petry H; Ferreira V
Mol Ther; 2017 Aug; 25(8):1831-1842. PubMed ID: 28596114
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion.
Tse LV; Klinc KA; Madigan VJ; Castellanos Rivera RM; Wells LF; Havlik LP; Smith JK; Agbandje-McKenna M; Asokan A
Proc Natl Acad Sci U S A; 2017 Jun; 114(24):E4812-E4821. PubMed ID: 28559317
[TBL] [Abstract][Full Text] [Related]
10. Overcoming preexisting humoral immunity to AAV using capsid decoys.
Mingozzi F; Anguela XM; Pavani G; Chen Y; Davidson RJ; Hui DJ; Yazicioglu M; Elkouby L; Hinderer CJ; Faella A; Howard C; Tai A; Podsakoff GM; Zhou S; Basner-Tschakarjan E; Wright JF; High KA
Sci Transl Med; 2013 Jul; 5(194):194ra92. PubMed ID: 23863832
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.
Lotfinia M; Abdollahpour-Alitappeh M; Hatami B; Zali MR; Karimipoor M
Clin Exp Med; 2019 Aug; 19(3):289-298. PubMed ID: 31054018
[TBL] [Abstract][Full Text] [Related]
12. Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.
Perocheau DP; Cunningham S; Lee J; Antinao Diaz J; Waddington SN; Gilmour K; Eaglestone S; Lisowski L; Thrasher AJ; Alexander IE; Gissen P; Baruteau J
Hum Gene Ther; 2019 Jan; 30(1):79-87. PubMed ID: 30027761
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
[TBL] [Abstract][Full Text] [Related]
14. Engineered Capsids for Efficient Gene Delivery to the Retina and Cornea.
Frederick A; Sullivan J; Liu L; Adamowicz M; Lukason M; Raymer J; Luo Z; Jin X; Rao KN; O'Riordan C
Hum Gene Ther; 2020 Jul; 31(13-14):756-774. PubMed ID: 32578442
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
[TBL] [Abstract][Full Text] [Related]
16. Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach.
Havlik LP; Simon KE; Smith JK; Klinc KA; Tse LV; Oh DK; Fanous MM; Meganck RM; Mietzsch M; Kleinschmidt J; Agbandje-McKenna M; Asokan A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669336
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.
Mimuro J; Mizukami H; Shima M; Matsushita T; Taki M; Muto S; Higasa S; Sakai M; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
J Med Virol; 2014 Nov; 86(11):1990-7. PubMed ID: 24136735
[TBL] [Abstract][Full Text] [Related]
18. Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies.
Ito M; Takino N; Nomura T; Kan A; Muramatsu SI
Sci Rep; 2021 Apr; 11(1):9322. PubMed ID: 33927271
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy.
van der Marel S; Comijn EM; Verspaget HW; van Deventer S; van den Brink GR; Petry H; Hommes DW; Ferreira V
Inflamm Bowel Dis; 2011 Dec; 17(12):2436-42. PubMed ID: 21370319
[TBL] [Abstract][Full Text] [Related]
20. AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees.
Calcedo R; Wilson JM
Hum Gene Ther Clin Dev; 2016 Jun; 27(2):79-82. PubMed ID: 27314914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
